Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

• Status: NOT_YET_RECRUITING
• Trial end date: 2025-12-31

Summary

The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.

• Phase: PHASE2

Details

• Lead Sponsor: Fujian Cancer Hospital
• Treatments: Capecitabine; Cetuximab; Fluorouracil; Leucovorin; Oxaliplatin